TSHA

1.61

1.83% -0.03

Handel nachbörslich: 1.66 0.05 +3.11%

Taysha Gene Therapies Inc (TSHA)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$1.64

Offen:

$1.64

24-Stunden-Volumen:

1.63M

Relative Volume:

0.53

Marktkapitalisierung:

$329.96M

Einnahmen:

$12.87M

Nettoeinkommen (Verlust:

$-114.34M

KGV:

-1.8621

EPS:

-0.8646

Netto-Cashflow:

$-79.23M

1W Leistung:

-1.23%

1M Leistung:

+5.23%

6M Leistung:

-28.76%

1J Leistung:

-36.11%

1-Tages-Spanne:

$1.60

$1.71

1-Wochen-Bereich:

$1.58

$1.74

52-Wochen-Spanne:

$1.19

$4.32

Taysha Gene Therapies Inc Stock (TSHA) Company Profile

Firmenname

Taysha Gene Therapies Inc

Sektor

Healthcare (1169)

Branche

Biotechnology (678)

Telefon

(214) 612-0000

Adresse

3000 PEGASUS PARK DRIVE, DALLAS

Mitarbeiter

Twitter

Nächster Verdiensttermin

2024-11-12

Neueste SEC-Einreichungen

TSHA's Discussions on Twitter

Vergleichen Sie TSHA mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
TSHA Taysha Gene Therapies Inc	1.61	329.96M	12.87M	-114.34M	-79.23M	-0.8646
VRTX Vertex Pharmaceuticals Inc	484.24	124.35B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	700.33	76.56B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	644.48	39.16B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	250.59	32.44B	2.25B	-278.16M	-42.59M	-2.17
BNTX Biontech Se Adr	120.01	28.77B	3.30B	-501.07M	1.03B	-2.1146

Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-06-27	Eingeleitet	BMO Capital Markets	Outperform
2024-04-09	Eingeleitet	Piper Sandler	Overweight
2023-02-01	Herabstufung	Jefferies	Buy → Hold
2023-01-27	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2022-11-09	Herabstufung	Goldman	Buy → Neutral
2022-03-09	Eingeleitet	Robert W. Baird	Outperform
2022-03-01	Eingeleitet	Wells Fargo	Overweight
2022-02-18	Eingeleitet	SMBC Nikko	Outperform
2021-12-16	Eingeleitet	Guggenheim	Buy
2021-07-16	Eingeleitet	Needham	Buy
2021-06-24	Eingeleitet	Truist	Buy
2021-06-15	Eingeleitet	BTIG Research	Buy
2021-06-09	Eingeleitet	Wedbush	Outperform
2021-06-08	Eingeleitet	JMP Securities	Mkt Outperform
2021-05-19	Eingeleitet	Cantor Fitzgerald	Overweight
2021-05-11	Fortgesetzt	Jefferies	Buy
2021-02-24	Eingeleitet	William Blair	Outperform
2021-01-05	Eingeleitet	Oppenheimer	Outperform
2020-10-19	Eingeleitet	Chardan Capital Markets	Buy
2020-10-19	Eingeleitet	Goldman	Buy
2020-10-19	Eingeleitet	Jefferies	Buy
2020-10-19	Eingeleitet	Morgan Stanley	Overweight

Alle ansehen

Taysha Gene Therapies Inc Aktie (TSHA) Neueste Nachrichten

Feb 21, 2025

Taysha Gene Therapies (TSHA) Projected to Post Earnings on Wednesday - Defense World

Feb 21, 2025

Feb 20, 2025

Taysha Gene Therapies to Release Full-Year 2024 Financial - GlobeNewswire

Feb 20, 2025

Feb 19, 2025

Taysha Gene Therapies to Release Full-Year 2024 Financial Results and Host Conference Call and Webcast on February 26 - The Manila Times

Feb 19, 2025

Gene Therapy Pioneer Taysha Readies Crucial 2024 Financial DisclosureHere's When - StockTitan

Feb 19, 2025

Feb 17, 2025

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives $6.63 Average Price Target from Brokerages - Defense World

Feb 17, 2025

Feb 15, 2025

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Shares Sold by SG Americas Securities LLC - Defense World

Feb 15, 2025

Feb 14, 2025

Taysha Gene Therapies (NASDAQ:TSHA) Shares Up 1.3%Time to Buy? - MarketBeat

Feb 14, 2025

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Rating of "Buy" from Brokerages - MarketBeat

Feb 14, 2025

Feb 12, 2025

Critical Analysis: Creative Medical Technology (NASDAQ:CELZ) vs. Taysha Gene Therapies (NASDAQ:TSHA) - Defense World

Feb 12, 2025

Feb 07, 2025

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Feb 07, 2025